Results 1 to 10 of about 16,284 (266)
Iontophoresis of Endothelin Receptor Antagonists in Rats and Men [PDF]
PLoS ONE, 2012 The treatment of scleroderma-related digital ulcers is challenging. The oral endothelin receptor antagonist (ERA) bosentan has been approved but it may induce liver toxicity. The objective of this study was to test whether ERAs bosentan and sitaxentan could be locally delivered using iontophoresis.Cathodal and anodal iontophoresis of bosentan and ...
Jean-Luc Cracowski +21 more
doaj +9 more sources
Endothelin Receptor Antagonists in Kidney Disease [PDF]
International Journal of Molecular Sciences, 2023 Endothelin (ET) is found to be increased in kidney disease secondary to hyperglycaemia, hypertension, acidosis, and the presence of insulin or proinflammatory cytokines. In this context, ET, via the endothelin receptor type A (ETA) activation, causes sustained vasoconstriction of the afferent arterioles that produces deleterious effects such as ...
Irene Martínez-Díaz +7 more
openaire +4 more sources
Endothelin receptor antagonists for pulmonary arterial hypertension [PDF]
Cochrane Database of Systematic Reviews, 2009 Pulmonary arterial hypertension is a devastating disease that leads to right heart failure and premature death. Endothelin receptor antagonists have shown efficacy in the treatment of pulmonary arterial hypertension.To evaluate the efficacy of endothelin receptor antagonists (ERAs) in pulmonary arterial hypertension.We searched the Cochrane Central ...
Kunshen Liu +4 more
openaire +6 more sources
Endothelin Receptors and Their Antagonists
Seminars in Nephrology, 2015 All three members of the endothelin (ET) family of peptides, ET-1, ET-2, and ET-3, are expressed in the human kidney, with ET-1 being the predominant isoform. ET-1 and ET-2 bind to two G-protein-coupled receptors, ETA and ETB, whereas at physiological concentrations ET-3 has little affinity for the ET(A) receptor.
Maguire, Janet J, Davenport, Anthony P
openaire +4 more sources
Endothelin‐1 and Endothelin Receptor Antagonists in Cardiovascular Remodeling
Proceedings of the Society for Experimental Biology and Medicine, 1999 Endothelins build a peptide family composed of three isoforms, each of them containing 21 amino acids. Endothelin‐1 is the isoform mainly responsible for any cardiovascular action and therefore the sole scope of this review. Endothelin‐1 is the most potent endogenous vasoconstrictor known; in addition it acts as a potent (co)mitogen.
Klaus Münter, Michael Kirchengast
openaire +3 more sources
Endothelin B receptor-mediated vasoconstriction induced by endothelin A receptor antagonist [PDF]
Cardiovascular Research, 1998 The vasoconstrictor effect of endothelins (ET) is mediated by endothelin A (ETA) and endothelin B (ETB) receptors. Furthermore, ETB receptor stimulation results in release of vasodilators. Hence, ETA receptor antagonists should attenuate ET-mediated vasoconstriction. The aim of the present study was to evaluate and compare the effects of BQ-123, an ETA
Zhang, Y., Oliver, J., Horowitz, J.
openaire +4 more sources
BOSENTAN - endothelin receptor antagonist
International Journal of Human and Health Sciences (IJHHS), 2018 Activation of the endothelin system has been demonstrated in the plasma and lung tissue of PAH (Pulmonary Artery Hypertension) patients. Although it is not clear if the increases in endothelin plasma levels are a cause or a consequence of PH (Pulmonary Hypertension), the data supports a prominent role for the endothelin system in the pathogenesis of ...
Paras Passi +5 more
openaire +2 more sources
Antidiuretic Effects of the Endothelin Receptor Antagonist Avosentan [PDF]
Frontiers in Physiology, 2012 Several clinical studies have investigated the potential benefits of endothelin receptor antagonism in chronic pathologies such as diabetic kidney disease. However, fluid retention and edema have been identified as major side effects of endothelin receptor antagonists.
Ovidiu Constantin Baltatu +8 more
openaire +3 more sources
Endothelin Receptor Antagonists and Cardiovascular Disease [PDF]
Drugs in R & D, 1999 Adis Comment All drugs appearing in the Adis Profile Summary table have been selected based on information contained in RD 2 (1): 13-16 1174-5886/99/0007-0013/$02.00 ...
Blair Jarvis +2 more
openaire +2 more sources
Endothelin in hypertension: A role for receptor antagonists? [PDF]
Cardiovascular Research, 1998 The rapid development of endothelin-receptor antagonists has made the endothelin pathway a new therapeutic target in the treatment of cardiovascular diseases, only ten years after the report of its discovery. While the first clinical trials will help to position this new family of compounds in our therapeutic armament for the treatment of essential or ...
openaire +3 more sources